Q-omics provides the consensus-scored TTC39DP profile across patient tissues and cancer cell-line models. TTC39DP expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TTC39DP is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, TTC39DP RNA expression shows 9,909 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where TTC39DP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC39DP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC39DP survival associations across molecular data types. TTC39DP RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC39DP RNA expression–survival associations across cancer types. High TTC39DP expression shows unfavorable associations in LUSC, KICH and LGG, but favorable associations in KIRC, MESO and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TTC39DP RNA expression.
This table summarizes TTC39DP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TTC39DP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC39DP shows lower tumor expression in KICH, THCA and PRAD and higher tumor expression in KIRC, HNSC and LUSC. The KICH box plot shows higher TTC39DP RNA expression in normal versus tumor tissue (log2 FC = −0.062, t-test p < 0.001).
This table shows molecular features associated with TTC39DP in patient tissues and cancer cell lines. In patient samples, TTC39DP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
